Edwards Lifesciences Co. (NYSE:EW) Short Interest Update

Edwards Lifesciences Co. (NYSE:EW) was the target of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 8,490,000 shares, a decline of 28.7% from the February 13th total of 11,900,000 shares. Currently, 1.5% of the company’s shares are short sold. Based on an average trading volume of 4,740,000 shares, the short-interest ratio is presently 1.8 days.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded up $1.38 on Monday, reaching $70.67. 5,653,039 shares of the stock were exchanged, compared to its average volume of 4,563,261. The business has a 50 day moving average price of $71.68 and a two-hundred day moving average price of $70.34. The firm has a market capitalization of $41.55 billion, a price-to-earnings ratio of 10.14, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Analysts anticipate that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 6,500 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.75, for a total value of $492,375.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,555,402. This represents a 12.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 51,303 shares of company stock worth $3,715,776 over the last quarter. Insiders own 1.29% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Crowley Wealth Management Inc. purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $26,000. Vega Investment Solutions purchased a new position in Edwards Lifesciences during the fourth quarter worth approximately $27,000. Millstone Evans Group LLC purchased a new position in Edwards Lifesciences during the fourth quarter worth approximately $29,000. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences in the third quarter valued at approximately $30,000. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $30,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on EW. Citigroup increased their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Morgan Stanley increased their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their target price for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Finally, Piper Sandler boosted their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.